MENU
 

PRE TAX NTA |$3.76

Value as at close of business on 17 January 2024

Research: Smart Ageing

Swinburne research is helping to ensure that people retain their memory and brain function as they get older.

Australia’s population is ageing. In 2016, people aged over 65 made up 16% of the population – by 2097, it is predicted that this proportion will be 25%. As people age, their brains can deteriorate, which affects memory, attention and wellbeing.

Researchers at Swinburne’s Centre for Human Psychopharmacology have combined brain imaging, clinical trials, and psychometric and computerised cognitive testing techniques to improve our understanding of how and why the brain deteriorates with age.

Most importantly, they have also explored how this can be prevented or treated. The centre has conducted 50 clinical trials to investigate the effects of specific substances on cognition (memory, attention, processing speed), mood (stress, wellbeing) and mental health (anxiety, depression).

They have made several groundbreaking discoveries.

The Swinburne team found that people with poor cardiovascular function and stiffer arteries are at higher risk of cognitive decline and dementia. They further found that treatments that improve cardiovascular function can also improve brain function, by providing better blood flow to carry oxygen, glucose and nutrients to the brain.

In 2004, the team showed that Enzogenol, a medicine used for cardiovascular treatment, improved memory performance in older males at risk of cognitive decline. Swinburne’s research on Enzogenol opened up new potential applications in the brain health area, including migraine and attention deficit hyperactivity disorder. Enzo Bioactives made three patent applications based on the work in 2005, and Enzogenol sales have increased 5% each year since the study. In 2008, the centre also published research showing that using Pycnogenol (similar to Enzogenol) for three months significantly improved memory and reduced oxidative stress. In 2018, further research was published showing that greater oxidative stress predicted poorer memory in older participants.

The team also found two other treatments that can improve brain function in older people.

The first is Bacopa monnieri, a creeping perennial herb native to the wetlands of Australia, Europe, Africa, Asia, and North and South America. The team proved that the herb can improve memory and attention in older people. They also showed that it is more effective than modafinil – a medicine used to improve cognition – at improving memory if taken regularly.

The Swinburne research on B. monnieri led to a number of patents by Soho Flordis International and registration of KeenMind, a product containing a specific extract of B. monnieri, in 2015. Products have been launched in more than 10 countries, including Australia, South Africa, the United States and selected markets in Africa and Asia.

The second treatment is curcumin, the active ingredient of turmeric. Swinburne research was the first in the world to show that curcumin improved working memory and reduced tiredness in older people. This work has helped to create a new market for curcumin, and Swinburne’s research has been the basis for several products in Australia, Japan, Canada, the United States and Europe by Verdure Sciences.

This research has been enabled by Swinburne’s advanced neuroimaging facilities at the Brain Sciences Institute, which includes magnetic resonance imaging (MRI) to measure brain structure and function, electroencephalography (EEG) to measure brain electrical activity, and magnetoencephalography (MEG) to measure the magnetic fields of the brain. The latter uses one of only two MEG machines in Australia. Swinburne also has state-of-the-art laboratories 7 for human clinical trials, involving computerised cognitive methods developed by Swinburne over the past 30 years.

The combination of Swinburne’s world-class neuropsychological-testing facilities and research team has led to strong links with research institutes and leading industry sponsors, including Nestlé, Bayer, GSK Nutrition, Verdure Sciences, Blackmores, Soho Flordis International, Swisse, AtCor Medical, Horphag Research and Enzo Neutraceuticals.

 

To learn more about the research projects being conducted at the Centre for Human Psychopharmacology visit their website here.

Recent Posts

Read the latest insights
A curated list of HM1 investor updates, portfolio news and other interesting articles.
Read More
Nine top stock picks to prepare your portfolio for 2025
Health care, ride-sharing, and the emerging world of YouTube entertainers are among the industries leading investors have picked for growth in 2025.
Resources fundies reveal top picks ahead of ‘stellar’ 2025
Some of Australia’s biggest resources funds are gearing up for a bumper start to the new year.
Qiao Ma: finding killer companies, surviving the GFC & why founders win
Qiao Ma, Portfolio Manager of the Munro Partners joins Owen Rask on The Australian Investors Podcast.
10 top fund managers reveal their long-term stock picks
With valuations stretched and geopolitical tensions high, the new year offers plenty of potholes for investors. 
 

Nine top stock picks to prepare your portfolio for 2025

Health care, ride-sharing, and the emerging world of YouTube entertainers are among the industries leading investors have picked for growth in 2025.

Read More
January 21st, 2025
 

Resources fundies reveal top picks ahead of ‘stellar’ 2025

Some of Australia’s biggest resources funds are gearing up for a bumper start to the new year.

Read More
January 6th, 2025
 

Qiao Ma: finding killer companies, surviving the GFC & why founders win

Qiao Ma, Portfolio Manager of the Munro Partners joins Owen Rask on The Australian Investors Podcast.

Read More
January 6th, 2025
 

10 top fund managers reveal their long-term stock picks

With valuations stretched and geopolitical tensions high, the new year offers plenty of potholes for investors. 

Read More
December 28th, 2024
 

Rikki Bannan – Don’t get caught up in momentum

Conference Fund Manager Rikki Bannan, Executive Director at IFM Investors, joins Equity Mates to discuss her standout 2023 stock pick, Telix, and explore what opportunities lie ahead.

Read More
December 19th, 2024
 

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
December 10th, 2024
 

Nick Griffin – The Nvidia story is not over

Nick Griffin, Founding Partner & Chief Investment Officer of Munro Partners joined the Equity Mates podcast in their Summer Series.

Read More
December 9th, 2024
 

HM1 CEO Succession

Hearts and Minds Investments Limited advises that Paul Rayson intends to retire from the position of Chief Executive Officer, effective 19 February 2025.

Read More
December 5th, 2024
 

Trump unifies top investors in decade-long bullish outlook for US

Nick Moakes, CIO of the $72 billion Wellcome Trust, told the conference that too many investors were banking on a return to the ultra-low interest rates that prevailed over the past decade.

Read More
November 20th, 2024
 

These rock-star stock picks could get markets talking next year

Eleven rock stars of international and local funds management took to stage – each tasked with picking and pitching one company whose shares will take off over the next year.

Read More
November 18th, 2024
 

Is anyone brave or stupid enough to bet against America?

Stock pickers have been punished for betting against the US. The choice between consensus and contrarianism on American exceptionalism is now harder than ever.

Read More
November 17th, 2024
 

Sohn: NYSE-listed Estee Lauder’s Northcape Capital pick

Northcape Capital’s Fleur Wright this gives a rare opportunity to buy a high quality company at an attractive price.

Read More
November 15th, 2024
 

Sohn ASX stock pick: Ellerston Capital’s Chris Kourtis backs Perpetual

Chris Kourtis has put his biggest bet on embattled Perpetual – picking one of the most hated stocks on the ASX – that he believes will soon be the ‘cheapest listed asset manager of scale in the universe’.

Read More
November 15th, 2024
 

AI start-ups a threat to incumbent big companies

Paul Bassat predicts emerging artificial intelligence companies will disrupt sectors and overtake established incumbent companies just as rapidly as the seismic shifts that took place when the internet emerged in the mid-1990s.

Read More
November 15th, 2024
 

Howard Marks and Sohn’s big stars reveal seven rules for investing

Among the stock picks and stunts at the Sohh Hearts & Minds event, Howard Marks and Nick Moakes provided investors with long-term rules for playing markets.

Read More
November 15th, 2024
 

Sohn investors position for bullish but bumpy Trump ride

Australia and the rest of the world must adjust to a new Trump presidency that will deliver an expected bull market but also disruption, with the leader in waiting prepared to “create pain” to get his way.

Read More
November 15th, 2024
 

Sohn stock picker experts name best shares to invest in for year ahead

‍Don’t overlook down and out silver miners, legacy skincare brands ready for a revival and a big financial company suffering from a severe case of shareholder wealth destruction.

Read More
November 15th, 2024
 

Eleven stock tips from Sohn to get you through 2025

“There’s no finer place for the finance festival than in the festival city,” said Matthew Grounds. He, along with fellow Barrenjoey co-executive chairman Guy Fowler and investor Gary Weiss, is one of Sohn’s driving forces.

Read More
November 15th, 2024
 

Sohn Hearts & Minds Investments fund targets $1.5bn valuation

‍Hearts & Minds Investments chair Chris Cuffe is hoping for HM1 to grow to more than $1.5bn in the next five years.

Read More
November 14th, 2024
 

Galaxy Digital CEO Mike Novogratz believes bitcoin will hit $US100k

Bitcoin’s bounce to record highs in recent days is only the beginning of a fresh surge higher for cryptocurrency, says US billionaire Mike Novogratz.

Read More
November 9th, 2024
 

Why this New York hedge fund manager sees opportunity in European stocks

Influential New York-hedge fund manager Ricky Sandler will turn to Europe for his next stock pick.

Read More
November 6th, 2024
 

Antipodes’ Ross says short-term wealth hinges on US election

The portfolio manager says defensive stocks pose a bigger risk than the magnificent seven for investors that are overexposed to the American sharemarket.

Read More
November 5th, 2024
 

Concentration risk key for investors: Antipodes Partners’ Vihari Ross

The concentration risk in global stock indexes that has built up during the strong rise over the past year must now be a key consideration for global investors, according to Vihari Ross.

Read More
November 5th, 2024
 

The fundie betting big on China – with help from AI

Mr Mehta is sticking to his well-worn strategy: he’s hunting for companies across Asia that aren’t battling intense competition and have management teams focused on costs, cash generation and high payouts to shareholders.

Read More
November 5th, 2024
 

Why this fundie wants you to ‘wince’ at his stock picks

When fund managers come to pitch their favourite stock at the annual Sohn Hearts & Minds conference, there are two ways they can go: they can play it safe, or they can take a risk and shock the room.

 

Read More
October 29th, 2024
 

IFM Investors’ Rikki Bannan backs small cap investments to rebound after mixed performance

IFM Investors executive director Rikki Bannan believes this year could be a good one to invest in some select small cap stocks.

Read More
October 27th, 2024
 

Meet the 2024 Conference Managers

Following a global search, the Conference Fund Manager Selection Committee is pleased to share eleven new managers for 2024. 

Read More
October 22nd, 2024
 

Chris Kourtis is on a winning streak. Here’s his next ASX pick

Chris Kourtis of Ellerston Capital thinks he’s found another winner and thinks it’s the last chance to have a bite at the cherry before the strategy plays out.

Read More
October 21st, 2024
 

Why Ellerston Capital’s Chris Kourtis plans to back a ‘hated’ stock

Chris Kourtis of Ellerston Capital plans to tip one of the “most hated” stocks in Australia when he presents at the 2024 Sohn Hearts & Minds Conference.

Read More
October 21st, 2024
 

Alex Pollak champions rewards of disruptive investment

Alex Pollak’s funds management company Loftus Peak rode the Nvidia wave and he is now looking at more opportunities in disruptive industry stocks.

Read More
October 14th, 2024